HUP0103563A2 - Memória effektor T-sejtek modulálására szolgáló eljárás és készítmények - Google Patents
Memória effektor T-sejtek modulálására szolgáló eljárás és készítményekInfo
- Publication number
- HUP0103563A2 HUP0103563A2 HU0103563A HUP0103563A HUP0103563A2 HU P0103563 A2 HUP0103563 A2 HU P0103563A2 HU 0103563 A HU0103563 A HU 0103563A HU P0103563 A HUP0103563 A HU P0103563A HU P0103563 A2 HUP0103563 A2 HU P0103563A2
- Authority
- HU
- Hungary
- Prior art keywords
- lymphocytes
- memory effector
- subject
- lfa
- condition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 210000003162 effector t lymphocyte Anatomy 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 108010084313 CD58 Antigens Proteins 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010046851 Uveitis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 abstract 1
- 230000008595 infiltration Effects 0.000 abstract 1
- 238000001764 infiltration Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000005962 mycosis fungoides Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70507—CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A találmány tárgyát képezi eljárás olyan állapot prevenciójára vagykezelésére, amelyet az alábbiak jellemeznek: memória effektor T-limfociták beszűrődése emlősszervezet egy vagy több szervébe; és/vagyaz ilyen állapot társult ilyen T-limfocitákkal. Az eljárásbanemlősszervezetnek beadnak egy vagy több CD2-kötőágenst, például anti-LFA-3-antitesthomológot, anti-CD2-antitesthomológot, szolubilis LFA-3-polipeptidet, szolubilis CD2-polipeptidet, CD2-t vagy LFA-3-atmimetizáló ágenst, amelyek szelektíven képesek modulálni memóriaeffektor T-limfociták, előnyösen CD45RO-jelű T-limfociták számátés/vagy eloszlását, naiv T-limfocitákhoz hasonlítva. Egy másikeljárásban olyan állapotot kezelnek egy alanyban, amelynekpatogenezisében memória effektor T-limfociták játszanak szerepet,például pszoriázisos artritiszt, reumatoid artritiszt, szklerózismultiplexet, atópiás dermatitiszt, uveagyulladást, gyulladásosbélbetegséget, Crohn-betegséget, kifekélyesedő vastagbélgyulladástvagy kután T-sejtes limfómát. Az eljárásban az alanynak szinténbeadnak hatásos mennyiségű, találmány szerinti CD2-kötőágenst. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9845698P | 1998-08-31 | 1998-08-31 | |
PCT/US1999/020026 WO2000012113A2 (en) | 1998-08-31 | 1999-08-31 | Method of modulating memory effector t-cells using a cd2-binding agent, and compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0103563A2 true HUP0103563A2 (hu) | 2002-01-28 |
HUP0103563A3 HUP0103563A3 (en) | 2004-04-28 |
Family
ID=22269362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0103563A HUP0103563A3 (en) | 1998-08-31 | 1999-08-31 | Method of modulating memory effector t-cells and compositions |
Country Status (26)
Country | Link |
---|---|
US (2) | US20020009446A1 (hu) |
EP (1) | EP1109570B1 (hu) |
JP (1) | JP2002523071A (hu) |
KR (1) | KR20010085687A (hu) |
CN (1) | CN100473417C (hu) |
AT (1) | ATE306932T1 (hu) |
AU (1) | AU764020B2 (hu) |
BR (1) | BR9913285A (hu) |
CA (1) | CA2339299C (hu) |
CZ (1) | CZ298238B6 (hu) |
DE (1) | DE69927831T2 (hu) |
DK (1) | DK1109570T3 (hu) |
EA (1) | EA005948B1 (hu) |
EE (1) | EE200100123A (hu) |
ES (1) | ES2252999T3 (hu) |
HK (2) | HK1038186A1 (hu) |
HU (1) | HUP0103563A3 (hu) |
IL (2) | IL141486A0 (hu) |
IS (1) | IS5848A (hu) |
MX (1) | MXPA01002111A (hu) |
NO (1) | NO20010956L (hu) |
NZ (1) | NZ510831A (hu) |
PL (1) | PL346339A1 (hu) |
TR (1) | TR200100607T2 (hu) |
WO (1) | WO2000012113A2 (hu) |
ZA (1) | ZA200101213B (hu) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
ES2252999T3 (es) * | 1998-08-31 | 2006-05-16 | Biogen Idec Ma Inc. | Modulacion de celulas t efectoras y de memoria con un ligando de cd2. |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
WO2002060480A1 (en) * | 2001-02-01 | 2002-08-08 | Biogen, Inc. | Methods for treating or preventing skin disorders using cd2-binding agents |
AU2002320352A1 (en) * | 2001-07-24 | 2003-02-17 | Biogen Idec Ma Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
EP1641827A2 (en) * | 2003-06-27 | 2006-04-05 | Biogen Idec MA Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
WO2005035586A1 (ja) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
MXPA06008918A (es) * | 2004-02-06 | 2007-03-07 | Astellas Llc | Metodos de tratamiento de trastornos de la piel. |
US20080020383A1 (en) * | 2004-05-04 | 2008-01-24 | Genaissance Pharmaceuticals, Inc. | Haplotype Markers And Methods Of Using The Same To Determine Response To Treatment |
EP1750747A1 (en) * | 2004-05-07 | 2007-02-14 | Astellas US LLC | Soluble lfa-3 polypeptide for treating viral disorders |
WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
EP2021025B1 (en) * | 2006-05-12 | 2016-08-17 | ITH Immune Therapy Holdings AB | Method and means for treating inflammatory bowel disease |
CN101113459A (zh) * | 2007-07-16 | 2008-01-30 | 东莞太力生物工程有限公司 | 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用 |
WO2010029317A2 (en) | 2008-09-10 | 2010-03-18 | Ibd Column Therapies International Ab | Treating inflammatory conditions |
WO2014025198A2 (ko) * | 2012-08-09 | 2014-02-13 | 주식회사 한독 | Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 |
EP3972993A1 (en) * | 2019-05-21 | 2022-03-30 | Novartis AG | Variant cd58 domains and uses thereof |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4579844A (en) * | 1976-05-13 | 1986-04-01 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
DE3377363D1 (en) * | 1982-03-31 | 1988-08-18 | Ajinomoto Kk | Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4681760A (en) * | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
NZ215865A (en) * | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
US5047336A (en) * | 1985-10-30 | 1991-09-10 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides |
JPH0763830B2 (ja) * | 1985-11-26 | 1995-07-12 | アスモ株式会社 | ダイカスト鋳造金型への離型剤塗布方法 |
US5190859A (en) * | 1987-02-26 | 1993-03-02 | Dana-Farber Cancer Institute, Inc. | Purification of LFA-3 |
US4956281A (en) * | 1987-06-03 | 1990-09-11 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 |
US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US5185441A (en) * | 1988-08-26 | 1993-02-09 | Biogen, Inc. | Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3 |
WO1990008187A1 (en) * | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5122514A (en) * | 1990-04-23 | 1992-06-16 | Abbott Laboratories | Psoriasis treatment |
CA2081028C (en) * | 1991-03-12 | 1999-12-14 | Barbara P. Wallner | Cd2 binding domain of lymphocyte function associated antigen 3 |
MX9203138A (es) * | 1991-03-12 | 1992-09-01 | Biogen Inc | Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos. |
AU660312B2 (en) * | 1991-06-06 | 1995-06-22 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same |
US5511563A (en) * | 1991-06-21 | 1996-04-30 | Diamond; Donald A. | Apparatus and method for treating rheumatoid and psoriatic arthritis |
US6162432A (en) * | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
AU678141B2 (en) * | 1991-10-07 | 1997-05-22 | Astellas Us Llc | Methods of improving allograft or xenograft tolerance by administration of an LFA-3 or CD2 binding protein |
US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
US5951983A (en) * | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
US5730979A (en) * | 1993-03-05 | 1998-03-24 | Universite Catholique Delouvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
US5817311A (en) * | 1993-03-05 | 1998-10-06 | Universite Catholique De Louvain | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies |
US5795572A (en) * | 1993-05-25 | 1998-08-18 | Bristol-Myers Squibb Company | Monoclonal antibodies and FV specific for CD2 antigen |
NZ298712A (en) * | 1995-01-16 | 1998-12-23 | Commw Scient Ind Res Org | Fatty acid acyl group conjugates as therapeutic compounds |
ES2252999T3 (es) * | 1998-08-31 | 2006-05-16 | Biogen Idec Ma Inc. | Modulacion de celulas t efectoras y de memoria con un ligando de cd2. |
US6337337B1 (en) * | 1998-09-03 | 2002-01-08 | Carol J. Buck | Methods for treating disorders responsive to DHFR-inhibition |
WO2002060480A1 (en) * | 2001-02-01 | 2002-08-08 | Biogen, Inc. | Methods for treating or preventing skin disorders using cd2-binding agents |
WO2002098370A2 (en) * | 2001-03-02 | 2002-12-12 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
-
1999
- 1999-08-31 ES ES99968216T patent/ES2252999T3/es not_active Expired - Lifetime
- 1999-08-31 EP EP99968216A patent/EP1109570B1/en not_active Expired - Lifetime
- 1999-08-31 WO PCT/US1999/020026 patent/WO2000012113A2/en active IP Right Grant
- 1999-08-31 KR KR1020017002566A patent/KR20010085687A/ko not_active Application Discontinuation
- 1999-08-31 MX MXPA01002111A patent/MXPA01002111A/es active IP Right Grant
- 1999-08-31 CZ CZ20010725A patent/CZ298238B6/cs not_active IP Right Cessation
- 1999-08-31 PL PL99346339A patent/PL346339A1/xx not_active Application Discontinuation
- 1999-08-31 AT AT99968216T patent/ATE306932T1/de not_active IP Right Cessation
- 1999-08-31 IL IL14148699A patent/IL141486A0/xx active IP Right Grant
- 1999-08-31 DE DE69927831T patent/DE69927831T2/de not_active Expired - Fee Related
- 1999-08-31 EA EA200100304A patent/EA005948B1/ru not_active IP Right Cessation
- 1999-08-31 JP JP2000567227A patent/JP2002523071A/ja active Pending
- 1999-08-31 HU HU0103563A patent/HUP0103563A3/hu unknown
- 1999-08-31 BR BR9913285-0A patent/BR9913285A/pt not_active Application Discontinuation
- 1999-08-31 EE EEP200100123A patent/EE200100123A/xx unknown
- 1999-08-31 DK DK99968216T patent/DK1109570T3/da active
- 1999-08-31 CN CNB998103128A patent/CN100473417C/zh not_active Expired - Fee Related
- 1999-08-31 AU AU60244/99A patent/AU764020B2/en not_active Ceased
- 1999-08-31 TR TR2001/00607T patent/TR200100607T2/xx unknown
- 1999-08-31 CA CA002339299A patent/CA2339299C/en not_active Expired - Fee Related
- 1999-08-31 NZ NZ510831A patent/NZ510831A/xx unknown
-
2001
- 2001-02-13 ZA ZA200101213A patent/ZA200101213B/en unknown
- 2001-02-16 IS IS5848A patent/IS5848A/is unknown
- 2001-02-18 IL IL141486A patent/IL141486A/en not_active IP Right Cessation
- 2001-02-26 NO NO20010956A patent/NO20010956L/no not_active Application Discontinuation
- 2001-02-27 US US09/796,033 patent/US20020009446A1/en not_active Abandoned
- 2001-12-19 HK HK01108882A patent/HK1038186A1/xx not_active IP Right Cessation
-
2002
- 2002-02-26 HK HK02101435.9A patent/HK1040186A1/zh unknown
-
2006
- 2006-04-06 US US11/398,908 patent/US20060233796A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0103563A2 (hu) | Memória effektor T-sejtek modulálására szolgáló eljárás és készítmények | |
EP0735893A4 (en) | CHANGING THE IMMUNE RESPONSE BY USING PAN DR BINDING PROTEINS | |
YU46097A (sh) | Nova klasa estara i njihove farmaceutske smeše | |
FR2808689B1 (fr) | Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs | |
BG102469A (en) | Cleaning composition for personal hygiene | |
MY104535A (en) | Oral composition for the treatment of inflammatory bowel diseases. | |
ATE183514T1 (de) | Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten | |
BR9710689A (pt) | Processo para tratar diarr-ia aguda e para proporcionar terapia a um mam¡fero tendo diarr-ia e prepara-Æo terap-utica para redu-Æo de sintomas de diarr-ia | |
KR940003555A (ko) | 면역 염증성 장질환 치료용 약제학적 조성물 | |
MX9705569A (es) | Inhibidores de adhesion celular. | |
IL142728A0 (en) | The use of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases | |
FR2694192B1 (fr) | Produits contenant du taxol pour utilisation dans la thérapie du cancer. | |
MX9406552A (es) | Metodo, composiciones y dispositivos para la admi nistracion de polinucleotidos desnudos que codifi can peptidos biologicamente activos. | |
PT1053256E (pt) | Anticorpos para o receptor de morte 4 (dr4) e utilizações destes | |
IL119989A0 (en) | Pharmaceutical compositions for oral treatment of multiple sclerosis | |
Muller et al. | Inhibition of the H+/peptide cotransporter in the human intestinal cell line Caco-2 by cyclic AMP | |
HUP9900886A2 (hu) | Biszfoszfonátok alkalmazása immunszupresszív terápiával kapcsolatos csontvesztés megelőzésére és kezelésére alkalmas gyógyászati készítmények előállítására | |
DE69310528T2 (de) | Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft | |
BG102556A (en) | Orally applied pharmaceutical composition with modified release containing 5-asa, and a method for the treatment of intestinal diseases | |
ATE230609T1 (de) | Verfahren zur behandlung von entzündungen und zusammensetzungen dafür | |
HUP0101715A2 (hu) | Eljárások és készítmények reumatoid artritisz kezelésére | |
IL120503A0 (en) | Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them | |
EP1039931A4 (en) | MULTIVALENT RECOMBINANT ANTIBODIES FOR THE TREATMENT OF HUMAN RHINOVIRUS (HRV) INFECTIONS | |
UA27055C2 (uk) | Лікарський препарат імуhозаміhhої дії hа осhові клітиhhої суспеhзії та спосіб лікуваhhя сиhдрому hабутого імуhодефіциту (віл-іhфекції) з використаhhям цього препарату | |
Lotzová et al. | Direct evidence for the involvement of natural killer cells in bone marrow transplantation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |